MED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medifast Inc (MED) is not a good buy for a beginner, long-term investor at this time. The company is facing significant financial challenges with declining revenue, net income, and EPS. The technical indicators are bearish, and there are no strong proprietary trading signals to support a buy decision. Additionally, the analyst rating and price target downgrade reflect a lack of confidence in the company's near-term growth potential. While there are some positive developments in corporate governance, they are not sufficient to outweigh the financial and operational headwinds.
The technical indicators for MED are bearish. The MACD is negative and expanding downward, the RSI is neutral at 30.664, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 9.387 and resistance at 10.213.
Steamboat Capital has expressed confidence in the company's undervalued assets and growth potential in metabolic health.
Analysts have lowered the price target from $15 to $12, citing concerns about the company's ability to return to growth. Technical indicators and trading sentiment are bearish, with no significant hedge fund or insider activity.
In Q4 2025, Medifast reported a revenue drop to $75.1M (-36.90% YoY), a net income loss of -$18.1M (-2362.05% YoY), and an EPS decline to -1.65 (-2457.14% YoY). Gross margin also fell to 69.43 (-6.34% YoY), indicating significant financial struggles.
Stephens has downgraded the price target to $12 from $15 and maintained an Equal Weight rating. The firm emphasizes the need for growth in the coach count as a key factor for recovery.
